Molecular imaging-guided gene therapy of gliomas.
Gene therapy of patients with glioblastoma using viral and non-viral vectors, which are applied by direct injection or convection-enhanced delivery (CED), appear to be satisfactorily safe. Up to date, only single patients show a significant therapeutic benefit as deduced from single long-term survivors. Non-invasive imaging by PET for the identification of viable target tissue and for assessment of transduction efficiency shall help to identify patients which might benefit from gene therapy, while non-invasive follow-up on treatment responses allows early and dynamic adaptations of treatment options. Therefore, molecular imaging has a critical impact on the development of standardised gene therapy protocols and on efficient and safe vector applications in humans.
Rueger
Maria A
MA
Laboratory for Gene Therapy and Molecular Imaging, Max-Planck Institute for Neurological Research, Germany.
Winkeler
Alexandra
A
Thomas
Anne V
AV
Kracht
Lutz W
LW
Jacobs
Andreas H
AH
D000818:Animals; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D003952:Diagnostic Imaging / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D005910:Glioma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography; D016896:Treatment Outcome